Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
BIOA Stock — BioAge Labs, Inc.
BioAge Labs, Inc. (BIOA)
Updated October 16, 2026.
BIOA is a Stock. Total return is -73.6% over the past 2.1 years, 110.0 points behind SPY at 36.4%.
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic candidates for metabolic diseases, including BGE-102, a brain-penetrant small-molecule NLRP3 inhibitor in Phase 1 trials for atherosclerotic cardiovascular disease and diabetic macular edema, alongside APJ agonist programs for obesity. The company does not currently distribute income to shareholders. BioAge Labs appeals to investors seeking exposure to early-stage drug development in aging-related metabolic disease, with understanding that clinical-stage biotech carries substantial risk and does not generate current income.
BIOA performance versus SPY
Price and return data through 2026-10-16.
Total return is -73.6% over the past 2.1 years, 110.0 points behind SPY at 36.4%. Over the past year its total return — price change plus distributions reinvested — is -5.3%. Its deepest 1-year drawdown was 80.7%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -37.5% | — |
| 3M | -78.2% | — |
| 6M | -71.5% | — |
| YTD | -63.4% | — |
| 1Y | -5.3% | — |
| 2Y CAGR | — | -55.30% |
| Since inception (2.1 years) | -73.6% | -47.70% |
BIOA key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 09/26/2024
- Distribution frequency
- None
- Last close
- $4.84 (as of 2026-10-16)
- Market cap
- $222,141,040
- Average volume
- 867084.0
- Beta
- 1.081
- Payout ratio
- 0.0%
- EPS
- $-2.39
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
BIOA risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 80.7%.
Who may consider BIOA — and who may not
It is a weaker fit for investors who need monthly cash flow (BIOA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on BIOA
Frequently asked questions
Does BIOA pay monthly?
No. BIOA does not currently distribute.
When does BIOA pay a dividend?
BIOA does not currently distribute.
How has BIOA performed?
Total return is -73.6% over the past 2.1 years, 110.0 points behind SPY at 36.4%. Over the past year its total return — price change plus distributions reinvested — is -5.3%. Its deepest 1-year drawdown was 80.7%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.